Northwire Canada EditionFriday, July 17, 2026
Northwire
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
M&A / Property

Tempramed enters distribution partnership with Salomo

VIVI · Price

Executive Summary

  • Tempramed Technologies Ltd. has entered into a distribution partnership with Salomo Executive to expand its European footprint, specifically targeting the Netherlands, Belgium, and Luxembourg (Benelux region).
  • The partnership aims to make Tempramed's VIVI product portfolio widely accessible through bricks-and-mortar pharmacies, medical distributors, and medical-focused retail channels.
  • Salomo Executive will leverage its established network, including pharmacy chains with over 500 locations and independent pharmacies, to ensure efficient and scalable product introduction.

Key Details

  • Partnership Structure: Tempramed Technologies Ltd. partnered with Salomo Executive, a healthcare logistics and consultancy firm based in the Netherlands.
  • Target Market: The Benelux region (Netherlands, Belgium, Luxembourg), described as one of Europe's most advanced healthcare ecosystems, particularly in diabetes care.
  • Distribution Channels: Access will be provided through:
    • Leading pharmacy chains (over 500 locations).
    • Numerous independent pharmacies.
    • Medical wholesalers.
    • Diabetes-focused webshops.
  • Product Portfolio: The partnership focuses on Tempramed's VIVI product portfolio, which includes patented temperature-regulated storage solutions for injectable medications (e.g., insulin).
  • Market Context: The release highlights the growing demand for temperature-controlled storage, citing that the Netherlands has approximately 1.2 million people living with diabetes and an additional 1.3 million with prediabetes.
  • Company Background: Tempramed holds eight international patents and has FDA registration for its space-grade thermal insulation devices. Salomo Executive has prior experience with major pharmaceutical brands like Merck & Co. (MSD).

Notable Quotes

  • "We are thrilled to collaborate with Salomo Executive, whose deep expertise in health care logistics and omnichannel distribution aligns perfectly with Tempramed's global growth strategy," said Ron Nagar, chief executive officer of Tempramed. "This partnership marks an important step in our broader expansion across Europe and other key international markets... Together with Salomo Executive, we look forward to building a long-term partnership that will accelerate access to Tempramed's innovative solutions across Western Europe and beyond."
Read the original news release →

More from Tempramed Technologies Ltd